BBC News reported on Monday that an experimental COVID-19 vaccine has been approved for use by the Chinese military.
The Ad5-nCoV vaccine is one of 150 being investigated around the world to see if immunisation can protect people against the COVID-19 pandemic virus by teaching the body to recognise and fight off the disease.
Reportedly, this particular vaccine, developed by Can Sino Biologics and the Beijing Institute of Biotechnology in the Academy of Military Medical Sciences, was the first one to enter a clinical trial with human volunteers.
The Lancet medical journal had reported in late May 2020 that the study, involving 108 adults, found the vaccine was safe and appeared to generate a response by the body's immune system.
According to the BBC, it's unclear whether this means people who get the vaccine will then have immunity against COVID-19.
Currently, no vaccine has yet been approved for widespread commercial use against COVID-19.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100